CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
MK-8892 +1 moredrug
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Systolic blood pressure >110 and ≤140 mmHg (Panels A/B) or 140-175 mmHg with diastolic 90-105 mmHg (Panel C), measured on at least three occasions at screening
  • ✓Body Mass Index (BMI) between 18 and 32 kg/m²
  • ✓Healthy, except Panel C subjects may have mild to moderate hypertension
  • ✓No clinically significant abnormality on electrocardiogram (ECG)
Key exclusion· 9
  • ✕History of stroke, chronic seizures, or major neurological disorder
  • ✕History of clinically significant endocrine, gastrointestinal, cardiovascular (except mild to moderate hypertension), hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
  • ✕Functional disability that prevents rising from sitting to standing position
  • ✕History of cancer (malignancy)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01798849
NCT01798849Phase 1Completed
CompareCT.gov

A Single Rising Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8892

Merck Sharp & Dohme LLC·interventional·Posted Feb 26, 2013·Updated Jul 22, 2019

In Brief

A Phase 1 clinical trial evaluating MK-8892 and Placebo for MK-8892 for Pulmonary Arterial Hypertension. Completed, enrolled 25 participants.

Detailed Summary

This study will evaluate safety, tolerability and effects on central diastolic blood pressure (cDBP) of MK-8892 given as single oral doses in healthy male participants (Panel A and B) and in male participants with mild-to-moderate hypertension (Panel C).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 26, 2013
Enrollment StartMar 15, 2013
Primary CompletionJul 17, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.3 years ago

Interventions

MK-8892drug

Placebo for MK-8892drug